ClinicalTrials.gg
RecruitingNCT06865937Updated Feb 23, 2026

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)

An interventional study of Mobile Intervention for Social Recovery in Serious Mental Illness (mSITE) and Supportive Contact (SC) in Schizophenia Disorder and Schizoaffective Disorder, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by University of California, San Diego · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Psychotic Disorders by University of California, San Diego — 6 open to participants now, 7 under way, 1 of them phase 3. Psychotic Disorders · University of California, San Diego.

Planned enrollment
5th of 19
125 · median 106
Started
2025
with 2 others
No phase
11 of 20
5 open now
Registered
17th of 20
by date

Among the 20 studies in Psychotic Disorders by University of California, San Diego, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, and was the 17th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

6 of the 20 studies in Psychotic Disorders by University of California, San Diego are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Psychotic Disorders by University of California, San Diego, or all of them as a file.
02

Study summary

This randomized clinical trial will test a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social engagement in consumers with serious mental illness.

Read the detailed description

This study evaluates a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social behavior, and it also validates several new techniques for measuring social behavior. mSITE blends brief in-person psychotherapy with a context-triggered mobile smartphone intervention and remote telephone coaching. The investigators will conduct a randomized clinical trial of mSITE, evaluating whether the intervention leads to clinically significant changes in the frequency of social interactions in comparison to a therapist and device matched condition. The investigators will changes in outcome measures at baseline and Weeks 8, 18, and 30. If found to be effective, a scalable intervention that reduces social isolation in serious mental illness would have significant personal, societal, and economic impact.

03

Conditions studied

  • Schizophenia Disorder
  • Schizoaffective Disorder

Keywords

  • schizophrenia
  • serious mental illness
  • social engagement
  • randomized clinical trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary to participate and capacity to consent; Age 18 to 65;
  • Diagnosis of schizophrenia, schizoaffective, bipolar I disorder or major depression with history of psychosis based on a diagnostic interview and available medical record review;
  • Minimum level of social avoidance defined by a score of ≥ 2 on the Scale for the Assessment of Negative Symptoms (SANS) asociality item;
  • Be willing and able to speak English at ≥ 6th grade reading level (to read intervention workbook).

Exclusion criteria

Exclusion Criteria:

  • Prior cognitive-behavioral therapy in the past 2 years;
  • Greater than moderate disorganization on the PANSS (P2- Disorganization item >5);
  • Alcohol or substance dependence in past 3 months based on the diagnostic interview;
  • Level of care required interferes with outpatient therapy (e.g., hospitalized; severe medical illness);
  • Unable to adequately see or manually manipulate a phone;
  • Resident of an integrated housing facility that also provides treatment services.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    mobile Social Interaction Therapy by Exposure (mSITE)

    mSITE is a blended intervention that integrates a brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.

    Behavioral: Mobile Intervention for Social Recovery in Serious Mental Illness (mSITE)

  • Active comparator
    Supportive Contact (SC)

    The SC arm is a contact condition that will provide the same amount of individual in-person and coaching, and mobile device contact as the mSITE condition.

    Behavioral: Supportive Contact (SC)

Interventions

  • BehavioralMobile Intervention for Social Recovery in Serious Mental Illness (mSITE)

    mSITE is a blended intervention that integrates a brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching. Participants will attend weekly, in-person sessions for 8 weeks and then 15-minute, remote coaching sessions for 10 weeks. The intervention begins with setting a meaningful recovery goal and then the generic cognitive model is introduced and a simple thought challenging skill is trained to specifically address social avoidance behaviors and facilitate work toward recovery goals. Defeatist attitudes, social threat and avoidance behaviors that interfere with working on the goal are then modified using cognitive-behavioral therapy skills and practiced using role-plays.

  • BehavioralSupportive Contact (SC)

    The SC arm will match the mSITE arm on the same amount of individual in-person and coaching, and mobile device contact. Coaching sessions will be semi-structured and consist of setting recovery goals, check-in about symptoms and potential crisis management, flexible discussion involving psychoeducation, instructions for accessing community crisis lines and community resources, and symptom management behaviors that grow out of discussions, with only minimal therapist guidance.

06

What researchers measure

Primary outcomes

  1. Ecological Momentary Assessment

    Ecological Momentary Assessment (EMA) is a method of remote data collection that involves repeatedly sampling a participant's current behaviors, thoughts, mood, and experiences in real time, in their natural environments. The primary outcome in this study will be the number of social interactions.

    Time frame: Assess change from baseline in number of social interactions at Weeks 0, 8, 18, and 30.

  2. Clinical Assessment Interview for Negative Symptoms

    Measure changes in motivational negative symptoms on the Clinical Assessment Interview for Negative Symptoms (CAINS). The CAINS is a 13-item interview-based assessment of negative symptoms, and each item is rated from 0 (no impairment) to 4 (severe deficit) measuring the two negative symptom factors recommended in consensus reports: Expression and Motivation and Pleasure (MAP) across social, vocational and recreational domains. Total scores for each factor are computed. The range for the MAP is 0 - 36, and the range for the Expression factor is 0 - 16. Higher scores indicate more severe negative symptoms for both factors.

    Time frame: Assess change from baseline in number of social interactions at Weeks 0, 8, 18, and 30.

  3. Birchwood Social Functioning Scale

    Measure changes in functioning on the Birchwood Social Functioning Scale (SFS). The SFS is a self-report assessment of functioning with 7 subscales, and each item is rated from 0 to 3 with the exception of the Occupation/Employment subscale if a participant is in regular employment (scores range from 7-10 based upon type of work). The subscales and score ranges are: Social Engagement Withdrawal (0-15), Interpersonal Communication/Relationships (0-30), Prosocial Activities (0-66), Recreation (0-48), Independence-Performance (0-39), Independence-Competence (0-39), and Occupation/Employment (0-10). Higher scores indicate better functioning for all subscales.

    Time frame: Assess change from baseline in number of social interactions at Weeks 0, 8, 18, and 30.

  4. Positive And Negative Syndrome Scale

    The Positive And Negative Syndrome Scale (PANSS) is a 30-item interview that provides balanced representation of positive and negative symptoms and gauges their relationship to one another and to global psychopathology. Items are rated 1 (Absent) to 7 (Extreme) and summed across items for a total range of scores of 30-210. Higher scores indicate the presence of more severe symptoms.

    Time frame: Assess change from baseline in number of social interactions at Weeks 0, 8, 18, and 30.

  5. Passive sensing mobile application

    The passive sensing mobile application will measure the number of conversations. The conversations or specific content will not be recorded.

    Time frame: Assess change from baseline in number of social interactions at Weeks 0, 8, 18, and 30.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Per terms of the award, participant-level data will be uploaded to the NIMH Data Archive (NDA).

Time frame: Data will be uploaded according to NDA standard data submission periods. These periods are currently twice each year.

Access criteria: Data access is outlined in the current NDA Policy.

Data sharing details ↗ · nda.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Sep 2028, 38 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 38 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 10, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06865937
Responsible party
Eric Granholm (Professor, University of California, San Diego) — Principal investigator
First posted
Mar 10, 2025
Start date
Jul 1, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Feb 23, 2026

Study contacts

Jason Holden, PhD
Contact
jlholden@health.ucsd.edu
858-246-2517
Eric Granholm, PhD
Contact
egranholm@health.ucsd.edu
858-534-2542
Eric Granholm, PhD
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion